Market Cap 144.38M
Revenue (ttm) 103.46M
Net Income (ttm) -227.21M
EPS (ttm) N/A
PE Ratio 8.00
Forward PE 8.26
Profit Margin -219.61%
Debt to Equity Ratio -0.12
Volume 382,600
Avg Vol 656,212
Day's Range N/A - N/A
Shares Out 38.40M
Stochastic %K 67%
Beta 1.57
Analysts Sell
Price Target $12.33

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
JFais
JFais Mar. 21 at 6:53 PM
$IBRX showed us how valuation can benefit from moving forward in non-core geographies (on Friday PR'ing Anktiva approved in Macau, in January it was Saudi Arabia) $AGEN- much bias against this name for VERY valid reasons (*cough CEO), but France AAC authorization + Global Named Patient Programs already generated $4.2M out of the gate! for BOT + BAL along with >200 inquiries from 30+ countries (hat tip to smarter minds, I just took an initial gander at it)
0 · Reply
2_logs_higher
2_logs_higher Mar. 21 at 2:09 PM
$AGEN https://www.hmpgloballearningnetwork.com/site/onc/news/botensilimab-plus-balstilimab-demonstrates-promise-refractory-metastatic-colorectal
0 · Reply
Biotechguy21
Biotechguy21 Mar. 21 at 1:02 AM
$AGEN agenus juice is toxic. 30 years of a pos company. Just say no. 🤡🤡💩💩🤮🤮
0 · Reply
manny11419
manny11419 Mar. 20 at 11:23 PM
$AGEN So I review the income statement on the 10k, page 82 to get an idea on the sale of bot/bal in France. Revenue $4,238,000 Cost of that revenue $1,022,000 This is an extraordinary profit margin, granted inventory methods and other non disclosure paid services can alter those numbers, but as I noted previously, most, if not all of that sales occurred in December. So if we can ran $4 million per month that would be $48 million per year. Zydus will charge a profit for future product deliveries, but I believe we get a good enough margin to cut out a good chuck of expenses going forward.
2 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 7:52 PM
$AGEN https://www.thedevitolab.org/
1 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 7:51 PM
$AGEN DeVito Lab
0 · Reply
BakerBrother
BakerBrother Mar. 20 at 6:47 PM
$AGEN still way to early to actually buy any software shit cos. Look at those private equity tickers. They were so greedy they forgot to exit now they own the equity and the debt and all have the pleasure of having full control of equity investments worth zero.
0 · Reply
BakerBrother
BakerBrother Mar. 20 at 6:41 PM
$AGEN media gaslighting us into believing US can’t takeover Kharg island whenever USA decides it wants to. LOL. Time to cover my software shorts and put some of that into favorite biotech.
2 · Reply
Spartrap
Spartrap Mar. 20 at 1:55 PM
$AGEN sharing this also on the Agenus board as the trial uses BOT/BAL. GL.
3 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 1:40 PM
$AGEN Remember 3/20 close is option expiration, but more improtantly is G's Form 4 stock award date based upon today's closing price. Agen seems to trade down into the award allowing more shares to be handed out.
2 · Reply
Latest News on AGEN
Agenus to Host First 2026 Stakeholder Webcast

Jan 20, 2026, 6:24 PM EST - 2 months ago

Agenus to Host First 2026 Stakeholder Webcast


Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Dec 4, 2025, 1:43 AM EST - 3 months ago

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript


Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 10 months ago

Agenus Announces Virtual Annual Shareholders Meeting


Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 4, 2025, 2:38 PM EDT - 10 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang


Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 23, 2025, 3:09 PM EDT - 10 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide


Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 2:46 PM EDT - 11 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript


Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:30 AM EDT - 11 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates


Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:39 AM EDT - 1 year ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript


JFais
JFais Mar. 21 at 6:53 PM
$IBRX showed us how valuation can benefit from moving forward in non-core geographies (on Friday PR'ing Anktiva approved in Macau, in January it was Saudi Arabia) $AGEN- much bias against this name for VERY valid reasons (*cough CEO), but France AAC authorization + Global Named Patient Programs already generated $4.2M out of the gate! for BOT + BAL along with >200 inquiries from 30+ countries (hat tip to smarter minds, I just took an initial gander at it)
0 · Reply
2_logs_higher
2_logs_higher Mar. 21 at 2:09 PM
$AGEN https://www.hmpgloballearningnetwork.com/site/onc/news/botensilimab-plus-balstilimab-demonstrates-promise-refractory-metastatic-colorectal
0 · Reply
Biotechguy21
Biotechguy21 Mar. 21 at 1:02 AM
$AGEN agenus juice is toxic. 30 years of a pos company. Just say no. 🤡🤡💩💩🤮🤮
0 · Reply
manny11419
manny11419 Mar. 20 at 11:23 PM
$AGEN So I review the income statement on the 10k, page 82 to get an idea on the sale of bot/bal in France. Revenue $4,238,000 Cost of that revenue $1,022,000 This is an extraordinary profit margin, granted inventory methods and other non disclosure paid services can alter those numbers, but as I noted previously, most, if not all of that sales occurred in December. So if we can ran $4 million per month that would be $48 million per year. Zydus will charge a profit for future product deliveries, but I believe we get a good enough margin to cut out a good chuck of expenses going forward.
2 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 7:52 PM
$AGEN https://www.thedevitolab.org/
1 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 7:51 PM
$AGEN DeVito Lab
0 · Reply
BakerBrother
BakerBrother Mar. 20 at 6:47 PM
$AGEN still way to early to actually buy any software shit cos. Look at those private equity tickers. They were so greedy they forgot to exit now they own the equity and the debt and all have the pleasure of having full control of equity investments worth zero.
0 · Reply
BakerBrother
BakerBrother Mar. 20 at 6:41 PM
$AGEN media gaslighting us into believing US can’t takeover Kharg island whenever USA decides it wants to. LOL. Time to cover my software shorts and put some of that into favorite biotech.
2 · Reply
Spartrap
Spartrap Mar. 20 at 1:55 PM
$AGEN sharing this also on the Agenus board as the trial uses BOT/BAL. GL.
3 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 1:40 PM
$AGEN Remember 3/20 close is option expiration, but more improtantly is G's Form 4 stock award date based upon today's closing price. Agen seems to trade down into the award allowing more shares to be handed out.
2 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 12:09 PM
$AGEN AI needs to learn how to spell Agenus , and BOT + BAL. The First Immunotherapy That Works for Most Colon Cancer https://www.youtube.com/watch?v=kaFwdDPwi14
4 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 11:55 AM
$AGEN Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives BOT + BAL referenced in footnote 52 Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, Wilky BA, Pimentel A, Mahadevan D, Balmanoukian AS, et al. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat Med. 2024;30:2558–67. https://link.springer.com/article/10.1186/s12967-026-08020-5
1 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 11:51 AM
$AGEN posting 1 month and 1 day early Rise in Colorectal Cancer in Younger Populations Motivates Trials, Better Treatments The current standard of care for microsatellite stable colorectal cancer is four to five lines of traditional chemotherapy, followed by immunotherapy if refractory. Late-line immunotherapy with BOT+ BAL has a 20% to 30% response rate. Flipping the order, DeVito’s trial goes straight to immunotherapy, which has a promising advantage. “We don’t want patients to wait for what could deliver a durable response first, and with fewer side effects,” he explains. This is especially relevant for a young person, who may want to avoid short- and long-term side effects from chemo while having the potential to achieve better long-term disease control. Moreover, immunotherapy works better in other cancers when it is given before the tumor becomes resistant to chemotherapy or targeted therapy. https://physicians.dukehealth.org/articles/rise-colorectal-cancer-younger-populations-motivates-trials-better-treatments
0 · Reply
2_logs_higher
2_logs_higher Mar. 20 at 11:49 AM
0 · Reply
Biotechguy21
Biotechguy21 Mar. 20 at 11:01 AM
$AGEN after all this time and always failing now this POS will really suck you in and pull the rug. 🤡🤡🤡🤡
0 · Reply
ajwinner81
ajwinner81 Mar. 20 at 8:41 AM
0 · Reply
joechuck71
joechuck71 Mar. 20 at 1:30 AM
Agenus stock price target reaffirmed at $8 by B.Riley on revenue growth By Analyst Ratings Published 03/17/2026, 11:20 AM $AGEN https://www.investing.com/news/analyst-ratings/agenus-stock-price-target-reaffirmed-at-8-by-briley-on-revenue-growth-93CH-4566152
3 · Reply
Biotechguy21
Biotechguy21 Mar. 20 at 12:46 AM
$AGEN funny how this baby blocks the only people who know what they are talking about!
0 · Reply
BakerBrother
BakerBrother Mar. 19 at 11:02 PM
$AGEN whst’s happening next with the Duke study?
0 · Reply
tyrus6
tyrus6 Mar. 19 at 8:06 PM
$AGEN Yet another post from you that isn't AGEN well. Added to the list.
2 · Reply
2_logs_higher
2_logs_higher Mar. 19 at 7:48 PM
$AGEN Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer https://www.hmpgloballearningnetwork.com/site/onc/news/botensilimab-plus-balstilimab-demonstrates-promise-refractory-metastatic-colorectal
0 · Reply
joechuck71
joechuck71 Mar. 19 at 7:06 PM
$AGEN leak
1 · Reply